SG11201901137UA - Silk-derived protein for treating inflammation - Google Patents

Silk-derived protein for treating inflammation

Info

Publication number
SG11201901137UA
SG11201901137UA SG11201901137UA SG11201901137UA SG11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA SG 11201901137U A SG11201901137U A SG 11201901137UA
Authority
SG
Singapore
Prior art keywords
international
silk
sdp
minnesota
rule
Prior art date
Application number
SG11201901137UA
Inventor
Brian D Lawrence
David W Infanger
Original Assignee
Silk Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silk Technologies Ltd filed Critical Silk Technologies Ltd
Publication of SG11201901137UA publication Critical patent/SG11201901137UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property --11` . 1#11101111 0 11101 HOE 3E1 0 0111E011H MO Ell 0011110 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ..../.- WO 2018/031973 Al 15 February 2018 (15.02.2018) WIPOIPCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61F 2/14 (2006.01) A61K 47/42 (2017.01) kind of national protection available): AE, AG, AL, AM, A61K 38/17 (2006.01) CO7K 14/435 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, PCT/US2017/046659 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (22) International Filing Date: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 12 August 2017 (12.08.2017) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/374,532 12 August 2016 (12.08.2016) US kind of regional protection available): ARIPO (BW, GH, 62/407,863 13 October 2016 (13.10.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 62/467,697 06 March 2017 (06.03.2017) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: SILK TECHNOLOGIES, LTD. [US/US]; EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 3700 Annapolis Ln N, Ste 105, Plymouth, Minnesota 55447 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (US). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (72) Inventors: LAWRENCE, Brian D.; 51 Sandpiper Road, KM, ML, MR, NE, SN, TD, TG). _ Tampa, Florida 33609 (US). INFANGER, David W.; 6236 = Troy Lane North, Maple Grove, Minnesota 55311 (US). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) = (74) Agent: HAUKAAS, Michael H.; 5100 Eden Avenue, Suite _ 303, Edina, Minnesota 55436 (US). (54) Title: SILK-DERIVED PROTEIN FOR TREATING INFLAMMATION = 1 . 5 — A e.v '••••••4 •••4 ee4v e••••0 .••• 4 1.0 = c*:•:1 ... 4 :::::::: NAN% ,:o ' ::o .:.:4 ox *4 0:4 4 , , H202 SIGNAL X: M 1......„ I I • • • (FOLD CONTROL) 0:+:; :* 1 .*x M 4:o 0 t i m, *:* 0.•40 = 4...0 SW4 I 1 = g C + • :: e••••0 • :•N • •• •4 C.:4•4 1,••11 + :4 W9 ......v ow : • A k x.:4 . A 4444 M _ 1-1 '• M IN CT - - 1 4.) M © -- -- GC (57) : Described herein are methods for reducing proteins (SDP) or a fraction thereof to a subject having 0 conditions and wounds, including corneal wounds, comprising N described herein. ;;;$ an 0.5% P A S F inflammation inflammatory condition. the topical a Fig. by administration 1 . 0 % SDP 5 administration The methods a of 5.0% SDP-4 of an effective amount of silk-derived include the treatment of inflammatory an effective amount of SDP material as C [Continued on next page] WO 2018/031973 Al MIDEDIMOHNOBEIERIMIDEMEIERVON Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of
SG11201901137UA 2016-08-12 2017-08-12 Silk-derived protein for treating inflammation SG11201901137UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662374532P 2016-08-12 2016-08-12
US201662407863P 2016-10-13 2016-10-13
US201762467697P 2017-03-06 2017-03-06
PCT/US2017/046659 WO2018031973A1 (en) 2016-08-12 2017-08-12 Silk-derived protein for treating inflammation

Publications (1)

Publication Number Publication Date
SG11201901137UA true SG11201901137UA (en) 2019-03-28

Family

ID=61163249

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901137UA SG11201901137UA (en) 2016-08-12 2017-08-12 Silk-derived protein for treating inflammation

Country Status (10)

Country Link
US (2) US11242367B2 (en)
EP (1) EP3496662A4 (en)
JP (1) JP2019531334A (en)
KR (1) KR102275012B1 (en)
CN (1) CN109862851A (en)
AU (1) AU2017310520A1 (en)
CA (1) CA3033507A1 (en)
MX (1) MX2019001633A (en)
SG (1) SG11201901137UA (en)
WO (1) WO2018031973A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2781114T3 (en) * 2014-08-20 2020-08-28 Silk Tech Ltd Protein composition derived from fibroin
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
AU2020288624A1 (en) 2019-06-04 2022-02-03 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
KR102374291B1 (en) * 2019-09-10 2022-03-14 강릉원주대학교산학협력단 Feed additive composition containing natural pozzolan
JP2023502591A (en) * 2019-11-15 2023-01-25 シルク テクノロジーズ、リミテッド Stable formulation of silk-derived proteins
KR102194995B1 (en) * 2020-09-16 2020-12-28 장혜란 stabilization compoation of improved dried humoral diagnosis and its opplication method
CN114685825B (en) * 2022-03-22 2023-02-28 浙江大学 Preparation method of fibroin eutectic gel, product and application thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5931520B2 (en) 1979-03-22 1984-08-02 カネボウ株式会社 Method for producing silk fibroin peptide aqueous solution
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
JPH0767686A (en) 1993-09-06 1995-03-14 Shinano Kenshi Co Ltd Production of silk fibroin peptide having low molecular weight
US5760004A (en) 1994-11-21 1998-06-02 Protein Polymer Technologies, Inc. Chemical modification of repetitive polymers to enhance water solubility
JP3449658B2 (en) 1994-12-21 2003-09-22 杏林製薬株式会社 8-Alkoxyquinolonecarboxylic acid hydrate excellent in stability and method for producing the same
US5895645A (en) 1995-01-31 1999-04-20 Bausch & Lomb Incorporated Opthalmic solution for artificial tears
JPH08295697A (en) 1995-04-26 1996-11-12 Kanebo Ltd Production of aqueous solution of silk fibroin at high concentration
WO1999033899A1 (en) 1997-12-31 1999-07-08 Kimberly-Clark Worlwide, Inc. Method of reducing molecular weights and polydispersity indices of polymers of ethylene oxide
FR2774588B1 (en) 1998-02-11 2000-05-05 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NATURAL, RECOMBINANT ARACHNID SILK PROTEIN OR THE LIKE
AU761040B2 (en) 1998-08-21 2003-05-29 Kyorin Pharmaceutical Co. Ltd. Aqueous liquid preparations
JP2000143472A (en) 1998-11-10 2000-05-23 Hiroshi Akai Cosmetic having ultraviolet light-absorbing function
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
BR0109317A (en) 2000-07-14 2003-06-17 Allergan Inc Compositions containing alpha-2-adrenergic agonist components
BR0112461A (en) 2000-07-14 2003-07-22 Allergan Inc Compositions containing therapeutically active components having increased solubility
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20030206897A1 (en) 2000-09-13 2003-11-06 The Procter & Gamble Company Cosmetic compositions
IT1316885B1 (en) 2000-10-02 2003-05-13 Consorzio Per Gli Studi Uni PROCEDURE FOR THE PREPARATION OF A NON-WOVEN FABRIC IN SILK FIBER.
ATE420671T1 (en) 2001-10-25 2009-01-15 Univ Connecticut FIBROIN COMPOSITIONS AND METHODS FOR THE PRODUCTION THEREOF
EP1459728A4 (en) 2001-11-29 2005-04-20 Nat Inst Of Agrobio Sciences Emulsifier and process for producing the same
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
WO2004062697A2 (en) 2003-01-07 2004-07-29 Tufts University Silk fibroin materials and use thereof
US7060260B2 (en) 2003-02-20 2006-06-13 E.I. Du Pont De Nemours And Company Water-soluble silk proteins in compositions for skin care, hair care or hair coloring
US7193038B2 (en) 2003-02-28 2007-03-20 National Institute Of Agrobiological Sciences Extraction and utilization of cell growth-promoting peptides from silk protein
US7115388B2 (en) 2003-03-14 2006-10-03 National Institute Of Agrobiological Sciences Production of functional polypeptides originating from silk protein and use thereof
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
WO2005012606A2 (en) 2003-04-10 2005-02-10 Tufts University Concentrated aqueous silk fibroin solution and use thereof
US8008338B2 (en) 2003-06-03 2011-08-30 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
PL1654002T5 (en) 2003-08-07 2014-06-30 Allergan Inc Compositions for delivery of therapeutics into the eyes
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
ES2383525T3 (en) 2003-11-05 2012-06-21 Sarcode Bioscience Inc. Cell adhesion modulators
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
EP1609801A1 (en) 2004-06-25 2005-12-28 Technische Universität München Proteins of natural origin and materials made therefrom
JP4896017B2 (en) 2004-07-31 2012-03-14 バイオグランド シーオー エル ティー ディー Composition for improving brain disease or brain function
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
PT1881823E (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Compositions and methods for treatment of eye disorders
CA2624667C (en) 2005-10-05 2018-01-09 Commonwealth Scientific And Industrial Research Organisation Silk proteins containing coiled coil region
ES2752823T3 (en) 2006-03-31 2020-04-06 Vistakon Pharmaceuticals Llc Eye allergy treatment
WO2007130364A2 (en) 2006-05-01 2007-11-15 Riolan Technologies, Inc. Compositions, methods, and kits for treating dry eye
WO2008109138A1 (en) 2007-03-07 2008-09-12 Grune Guerry L Spf compositions
KR20100029217A (en) 2007-05-29 2010-03-16 트러스티즈 오브 터프츠 칼리지 Method for silk fibroin gelation using sonication
CN101194666A (en) 2007-11-28 2008-06-11 吴江市方霞企业信息咨询有限公司 Silkworm chrysalis fibroin protein functional foods
WO2009088119A1 (en) 2008-01-07 2009-07-16 Bioleaders Corporation Composition for preventing or treating dry eye syndrome comprising poly-gamma-glutamic acid
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US8569730B2 (en) 2008-07-08 2013-10-29 Sandisk 3D Llc Carbon-based interface layer for a memory device and methods of forming the same
EP2403551A4 (en) 2009-03-04 2014-02-26 Tufts College Silk fibroin systems for antibiotic delivery
WO2010123947A2 (en) 2009-04-20 2010-10-28 Allergan, Inc. Silk fibroin hydrogels and uses thereof
NZ596932A (en) 2009-06-05 2014-04-30 Allergan Inc Artificial tears and therapeutic uses
WO2011008842A2 (en) 2009-07-14 2011-01-20 Trustees Of Tufts College Electrospun silk material systems for wound healing
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US9603971B2 (en) 2010-03-05 2017-03-28 Trustees Of Tufts College Silk-based ionomeric compositions
US8309689B2 (en) 2010-05-20 2012-11-13 Taipei Medical University High yield dialysis-free process for producing organosoluble regenerated silk fibroin
EP2582360A4 (en) 2010-06-17 2014-01-22 Tufts University Trustees Of Tufts College Silk optical particles and uses thereof
WO2012170655A1 (en) 2011-06-07 2012-12-13 Cornell University Silk compositions and methods of using same
CN102860969A (en) 2011-07-07 2013-01-09 刘畅 Soybean eye cream
WO2013126799A1 (en) 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
US9056063B2 (en) 2012-03-13 2015-06-16 James E. Hanson Natural sunscreen composition
US20150079012A1 (en) 2012-04-20 2015-03-19 Trustees Of Tufts College Silk fibroin-based personal care compositions
EP3715345B8 (en) 2012-07-25 2024-05-29 Bausch + Lomb Ireland Limited Preparation of lfa-1 inhibitor
US20140235554A1 (en) 2013-02-12 2014-08-21 Brian Lawrence Ophthalmic formulation derived from silk protein
KR20230021768A (en) * 2013-03-15 2023-02-14 트러스티즈 오브 터프츠 칼리지 Low molecular weight silk compositions and stabilizing silk compositions
AU2014240170B2 (en) 2013-03-15 2018-05-17 Patheon Softgels Inc. Silk-based capsules
CN103239707A (en) 2013-05-22 2013-08-14 江苏紫石化工科技有限公司 Eye drop for treating myopia
JP6775751B2 (en) 2013-09-30 2020-10-28 エボルブド バイ ネイチャー， インコーポレイテッド Silk protein fragment composition and articles produced from it
AU2014353110B2 (en) 2013-11-19 2018-05-10 Cornell University Tissue scaffold materials for tissue regeneration and methods of making
ES2781114T3 (en) * 2014-08-20 2020-08-28 Silk Tech Ltd Protein composition derived from fibroin
US10758645B2 (en) * 2014-12-17 2020-09-01 Tufts University Injectable, flexible hydroxyapatite-silk foams for osteochondral and dental repair
CA3020342A1 (en) 2016-04-08 2017-11-23 Cornell University A method to enhance wound healing using silk-derived protein

Also Published As

Publication number Publication date
WO2018031973A1 (en) 2018-02-15
US20220332773A1 (en) 2022-10-20
EP3496662A1 (en) 2019-06-19
CA3033507A1 (en) 2018-02-15
CN109862851A (en) 2019-06-07
US11242367B2 (en) 2022-02-08
MX2019001633A (en) 2019-09-18
KR20190042608A (en) 2019-04-24
KR102275012B1 (en) 2021-07-07
JP2019531334A (en) 2019-10-31
AU2017310520A1 (en) 2019-03-21
US20190169243A1 (en) 2019-06-06
EP3496662A4 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
SG11201901137UA (en) Silk-derived protein for treating inflammation
SG11201909386SA (en) Composite dressings for improved granulation and reduced maceration with negative-pressure treatment
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201907034PA (en) Methods of treating influenza
SG11201909383PA (en) Customizable composite dressings for improved granulation and reduced maceration negative-pressure treatment
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201908790PA (en) Glucocorticoid receptor modulators to treat cervical cancer
SG11201900809TA (en) Combination steerable catheter and systems
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201811019TA (en) Device for cardiac valve repair and method of implanting the same
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201808804TA (en) A method to enhance wound healing using silk-derived protein
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201809605PA (en) Compositions for and method of treating acid-base disorders
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine